Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD

Blood (2019) 134 (Supplement_1): 3314.

https://doi.org/10.1182/blood-2019-131321

Published: 2019

Journal Articles

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A Sallman, MD, Jason B. Brayer, PhDMD, Xavier Poire, Violaine Havelange, Ahmad Awada, MD PhD, Philippe Lewalle, Kunle Odunsi, MD, Eunice S. Wang, MD, Caroline Lonez, PhD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Nathalie Braun, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3826.

https://doi.org/10.1182/blood-2019-128020

Published: 2019

Journal Articles

Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression

Rupal Ramakrishnan, Alexandra Achille, Tuan Nyugen, Ian Taylor, BS, Gabriel De Avila, BS, Raghunandanreddy Alugubelli, MS, Mark B. Meads, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD

Blood (2019) 134 (Supplement_1): 4392.

https://doi.org/10.1182/blood-2019-131966

Published: 2019

Journal Articles

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Ariel F Grajales-Cruz, MD, Cristian Ivan Rodriguez Arocho, MD, Ashley Rose, MD, Jamie Shapiro, PharmD, Elizabeth Finley-Oliver, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Taiga Nishihori, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Melissa Alsina, MD, Rachid Baz, MD

Blood (2019) 134 (Supplement_1): 3183.

https://doi.org/10.1182/blood-2019-129021

Published: 2019

Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD

Blood (2019) 134 (Supplement_1): 3189.

https://doi.org/10.1182/blood-2019-131451

Published: 2019

Journal Articles

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

Kenneth H. Shain, MD PhD, Daniel Hart, Ariosto Siqueira Silva, PhD, Raghunandanreddy Alugubelli, MS, Gabriel De Avila, BS, Praneeth Reddy Sudalagunta, PhD, Alexandre Tungesvik, MD, Amit Kulkarni, PhD, Carmelo Blancuicett, PhD MD, Hongyue Dai, PhD, Taiga Nishihori, MD, Jason B. Brayer, PhDMD, Brandon Blue, MD, Melissa Alsina, MD, Rachid Baz, MD, William S. Dalton, PhDMD

Blood (2019) 134 (Supplement_1): 5511.

https://doi.org/10.1182/blood-2019-132234

Published: 2019

Journal Articles

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1398.

https://doi.org/10.1182/blood-2018-99-114747

Published: 2018

Journal Articles

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

David A Sallman, MD, Tessa Kerre, MD, Xavier Poire, MD, Violaine Havelange, Philippe Lewalle, MD, Marco L. Davila, MD PhD, Eunice S. Wang, MD, Doreen Dekker, PhD, Sarah Snykers, PhD, Panagiota A. Sotiropoulou, PhD, Eytan Breman, Nathalie Braun, Caroline Lonez, PhD, Bikash Verma, MD DVM, Frédéric F. Lehmann, MD, Jason B. Brayer, PhDMD

Blood (2018) 132 (Supplement 1): 902.

https://doi.org/10.1182/blood-2018-99-111326

Published: 2018

Journal Articles

Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival

AGM Mostofa, PhD, Allison Distler, Mark B. Meads, PhD, Eva Sahakian, PhD, John J. Powers, BS, Tuan Nguyen, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD, Eduardo Sotomayor, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhD MD

Blood (2018) 132 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2018-99-119119

Published: 2018

Journal Articles

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Rachid Baz, MD, Jeffrey A Zonder, MD, Kenneth H Shain, MD PhD, Melissa Alsina, MD, Jason B. Brayer, PhDMD, Mark Melody, Joel G. Turner, PhD, Jana L Dawson, Jongphil Kim, Daniel M Sullivan, MD

Blood (2017) 130 (Supplement 1): 3095.

https://doi.org/10.1182/blood.V130.Suppl_1.3095.3095

Published: 2017

Journal Articles

HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma

Jason B. Brayer, PhDMD, Allison Distler, Mark B. Meads, PhD, Eva Sahakian, PhD, John J. Powers, BS, Tuan Nguyen, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Javier Pinilla-Ibarz, MD PhD, Eduardo Martin Sotomayor, MD, Ken H Shain, MD PhD

Blood (2017) 130 (Supplement 1): 1800.

https://doi.org/10.1182/blood.V130.Suppl_1.1800.1800

Published: 2017

Journal Articles

A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma

Jason B. Brayer, MDPhD, Eva Sahakian, PhD, John Powers, M.S., Mark B Meads, PhD, Susan Deng, Allison Distler, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Alejandro Villagra, PhD, Javier Pinilla-Ibarz, MD PhD, Eduardo M. Sotomayor, MD, Kenneth H. Shain, MD PhD

Blood (2014) 124 (21): 4715.

https://doi.org/10.1182/blood.V124.21.4715.4715

Published: 2014

Journal Articles

Concurrent Epstein Barr Virus Viremia and Hodgkin Lymphoma In Two Patients With Chronic Lymphocytic Leukemia

Samir Dalia, MD, Jason B. Brayer, MD, PhD, Julio C Chavez, MD, Celeste M. Bello, MD, Bijal D. Shah, MD, Pedro Horna, M.D., Hailing Zhang, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD, PhD

Blood (2013) 122 (21): 5290.

https://doi.org/10.1182/blood.V122.21.5290.5290

Published: 2013

Journal Articles

A Novel Role For Histone Deacetylase 11 (HDAC11) In Plasma Cell Differentation and Survival

Eva Sahakian, Ph.D, Jason B. Brayer, MD, PhD, John Powers, B.S., Mark Meads, PhD, Allison Distler, Susan Deng, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Javier Pinilla-Ibarz, MD, PhD, Eduardo M. Sotomayor, MD, Kenneth Shain, MD, PhD

Blood (2013) 122 (21): 1907.

https://doi.org/10.1182/blood.V122.21.1907.1907

Published: 2013

Journal Articles

Ligation of Toll-Like Receptor 5 (TLR5) by Flagellin Overcomes Antigen-Specific CD4+ T Cell Tolerance Via Inhibition of IL10 and Induction of IL12 in Antigen Presenting Cells (APCs).

Ildefonso Suarez, BS, FengDong Cheng, Jason B. Brayer, HW Wang, Horna Pedro, Sotomayor M. Eduardo

Blood (2004) 104 (11): 3443.

https://doi.org/10.1182/blood.V104.11.3443.3443

Published: 2004

NARROW

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma

A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma

Concurrent Epstein Barr Virus Viremia and Hodgkin Lymphoma In Two Patients With Chronic Lymphocytic Leukemia

A Novel Role For Histone Deacetylase 11 (HDAC11) In Plasma Cell Differentation and Survival

Ligation of Toll-Like Receptor 5 (TLR5) by Flagellin Overcomes Antigen-Specific CD4+ T Cell Tolerance Via Inhibition of IL10 and Induction of IL12 in Antigen Presenting Cells (APCs).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only